Inhibition of activity tryptophan hydroxylase-1 - the new conception in the treatment of mineral and bone disorders in chronić reanal failure.

2013/09/B/NZ7/00046

Keywords

Descriptors

  • NZ7_14: Farmacja, farmakoterapia, farmakologia

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

Voivodeship: podlaskie

Other projects carried out by the institution »

Principal investigator (from the host institution)

prof. Krystyna Pawlak

Number of co-investigators in the project: 9

Call

OPUS 5 – announced on 2013-03-15

Amount awarded
729 685 PLN
Project start date
2014-03-21
Project end date
2018-03-20
Project duration
48 months (the same as in the proposal)
Project status
Project settled

Equipment purchased [PL]

  1. Aparat spektrofotometr UV-Vis NanoDrop2000.
  2. Oprogramowanie Biokinetica v.4.0. Cost: 9 000 PLN
  3. Zamrażarka niskotemperaturowa z awaryjnym systemem chłodzenia (CO2), pojemność 500 l, stelaże, pojemniki niskotemperaturowe.. Cost: 95 000 PLN

Information in the final report

Publication in academic press/journals (5)

  1. Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats.

    Authors:
    Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K.
    Academic press:
    Biochim Biophys Acta Mol Basis Dis (year: 2019, volume: 1865, pages: 165528), Publisher: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bbadis.2019.08.004 – link to the publication
  2. The association between elevated levels of peripheral serotonin and its metabolite - 5-hydroxyindoleacetic acid and bone strength and metabolism in growing rats with mild experimental chronic kidney disease

    Authors:
    Pawlak D, Oksztulska-Kolanek E, Znorko B, Domaniewski T, Rogalska J, Roszczenko A, Brzóska MM, Pryczynicz A, Kemona A, Pawlak K
    Academic press:
    PLoS One (year: 2016, volume: 2016;11(10), pages: -), Publisher: Public Limbrary of Science
    Status:
    Published
    DOI:
    10.1371/journal.pone.0163526 – link to the publication
  3. LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.

    Authors:
    Pawlak D, Znorko B, Kalaska B, Domaniewski T, Zawadzki R, Lipowicz P, Doroszko M, Łebkowska U, Grabowski P, Pawlak K
    Academic press:
    Bone (year: 2018, volume: 113, pages: 124-136), Publisher: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bone.2018.05.022 – link to the publication
  4. The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.

    Authors:
    Pawlak D, Domaniewski T, Znorko B, Pawlak K
    Academic press:
    Expert Opin Ther Targets (year: 2019, volume: 23, pages: 353-364), Publisher: Taylor & Francis Online
    Status:
    Published
    DOI:
    10.1080/14728222.2019.1586883 – link to the publication
  5. The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease.

    Authors:
    Pawlak D, Domaniewski T, Znorko B, Oksztulska-Kolanek E, Lipowicz P, Doroszko M, Karbowska M, Pawlak K.
    Academic press:
    Bone (year: 2017, volume: 105, pages: 46032), Publisher: Elsevier
    Status:
    Published
    DOI:
    10.1016/j.bone.2017.08.004 – link to the publication

Articles in post-conference publications (8)

  1. Tryptophan hydroxylase-1 inhibitor – LP533401 by decrease serum phosphorus affected bone mineral density in experimental chronic kidney disease

    Authors:
    Pawlak D, Znorko B, Zawadzki R, Łebkowska U, Domaniewski T, J Rogalska, Brzoska M, Pawlak K
    Conference:
    Osteoporosis Conference 2016, Birmingham, UK, 7-9 November 2016. (year: 2016, pages: S682), Publisher: Springer
    Date:
    conference 7-9 listopada 2016
    Status:
    Published
  2. The treatment with LP533401 improved bone mineral density in rats with experimental chronic kidney disease.

    Authors:
    Pawlak K, Znorko B, Zawadzki R, Łebkowska U, Domaniewski T, Pawlak D
    Conference:
    Osteoporosis Conference 2016, Birmingham, UK, 7-9 November 2016. (year: 2016, pages: S682), Publisher: Springer
    Date:
    conference 7-9 listopad 2016
    Status:
    Published
  3. Wpływ inhibitora hydroksylazy tryptofanu - LP533401 na gospodarkę witaminy D w doświadczalnym modelu niewydolności nerek u szczura.

    Authors:
    Pawlak D, Domaniewski T, Znorko B, Mor A, Pawlak K.
    Conference:
    XXIV Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Nefrologicznego (year: 2018, pages: .), Publisher: Polskie Towarzystwo Nefrologiczne
    Date:
    conference 21-23 czerwiec
    Status:
    Published
  4. Wpływ terapii LP533401 na ekspresję transporterów wapnia w nerce w modelu eksperymentalnej niewydolności nerek u szczura.

    Authors:
    Pawlak K, Domaniewski T, Znorko B, Grabowski P, Pawlak D.
    Conference:
    XXIV Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Nefrologicznego (year: 2018, pages: .), Publisher: Polskie Towarzystwo Nefrologiczne
    Date:
    conference 21-23 czerwiec
    Status:
    Published
  5. LP533401 treatment and disturbance of calciotropic hormones resulted in dysregulation of serotonin-dependent genes and reduction of osteoblast proliferation/differentiation in rats with chronic kidney disease.

    Authors:
    Pawlak K, Domaniewski T, Sieklucka B, Jakuc M, Pawlak D
    Conference:
    7th Central European Congress on Osteoporosis and Osteoarthritis (year: 2019, pages: 165-166), Publisher: Komitet Organizacyjny Kongresu
    Date:
    conference 27-28 wrzesień
    Status:
    Published
  6. The influence of tryptophan hydroxylase inhibitor LP533401 on kynurenine concentration in bone tissue in the experimental model of chronic kidney disease.

    Authors:
    Kalaska B, Mor A, Sieklucka B, Domaniewski T, Zawadzki R, Lebkowska U, Pawlak K, Pawlak D
    Conference:
    56th ERA-EDTA Congress (year: 2019, pages: .), Publisher: Nephrol Dial Transplant 2019, 34 (suppl.1), FP443
    Date:
    conference 13-16 czerwiec
    Status:
    Published
    DOI:
    link to the publication
  7. Wpływ LP533401 na wydalanie fosforanów i ekspresję genów zaangażowanych w reabsorpcję fosforanów w nerce w modelu eksperymentalnej niewydolności nerek u szczura.

    Authors:
    Pawlak K, Domaniewski T, Znorko B, Pawlak D.
    Conference:
    XXIII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego (year: 2017, pages: 44), Publisher: Polskie Towarzystwo Farmaceutyczne, Wydział Farmaceutyczny, Uniwersytet Jagielloński-Collegium Medicum
    Date:
    conference 19-22 wrzesień
    Status:
    Published
  8. Low expression of sclerostin (Sost) gene in the femur of rats with chronic kidney disease treated with inhibitor of type 1 tryptophan hydroxylase is associated with the improvement of femoral mineral status.

    Authors:
    Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K.
    Conference:
    7th Central European Congress on Osteoporosis and Osteoarthritis (year: 2019, pages: 169-170), Publisher: Komitet Organizacyjny Kongresu
    Date:
    conference 27-28 września
    Status:
    Published

« New search

Graphic design and implementation: Jakub Piotrowski